High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer

Akihiro Bessho, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Kazutaka Sunami, Yoshio Katayama, Hiromichi Yamane, Akio Hiraki, Mine Harada

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer) SCLC). Patients and Methods: Eleven patients aged 44 to 63 years old (5 with extensive disease [ED] and 6 with limited disease [LD]) were entered into this study. Induction chemotherapy consisted of 3 to 4 cycles of cisplatin and irinotecan for ED-SCLC, and cisplatin and etoposide for LD-SCLC. Patients with LD-SCLC received concurrent chest radiotherapy along with the first cycle of induction chemotherapy. After induction therapy, peripheral blood progenitor cells (PBPC) were collected following G-CSF administration during a recovery phase from high-dose etoposide (1500 mg/m2). Eight patients (4 with ED and 4 with LD) with adequate organ function were treated with HD-ICE (15 g/m2 ifosfamide, 1200 mg/m2 carboplatin and 1500 mg/m2 etoposide) followed by ABPCT. Results: Hematologic recovery was rapid and non-hematological toxicities were acceptable without treatment related mortality. In ED-SCLC, all of the 4 patients achieved complete response (CR) or near CR but developed a relapse of the isease. In LD-SCLC, 2 of 4 patients with LD-SCLC are alive in continuous CR for 18 and 21 months after the beginning of induction therapy. Conclusions: Despite a limited number of patients and short follow-up time, these preliminary results indicate that marrow-ablative therapy (HD-ICE) supported by ABPCT is feasible in the treatment of elderly patients with LD- and ED-SCLC.

Original languageEnglish
Pages (from-to)693-698
Number of pages6
JournalAnticancer Research
Volume19
Issue number1 B
Publication statusPublished - 1999

Fingerprint

Ifosfamide
Carboplatin
Cell Transplantation
Small Cell Lung Carcinoma
Etoposide
Blood Cells
Stem Cells
irinotecan
Induction Chemotherapy
Cisplatin
Therapeutics
Granulocyte Colony-Stimulating Factor
Radiotherapy
Thorax
Bone Marrow

Keywords

  • Autologous peripheral blood progenitor cell transplantation
  • Carboplatin
  • Etoposide
  • High-dose chemotherapy
  • Ifosfamide
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. / Bessho, Akihiro; Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Sunami, Kazutaka; Katayama, Yoshio; Yamane, Hiromichi; Hiraki, Akio; Harada, Mine.

In: Anticancer Research, Vol. 19, No. 1 B, 1999, p. 693-698.

Research output: Contribution to journalArticle

Bessho, A, Ueoka, H, Kiura, K, Tabata, M, Sunami, K, Katayama, Y, Yamane, H, Hiraki, A & Harada, M 1999, 'High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer', Anticancer Research, vol. 19, no. 1 B, pp. 693-698.
Bessho, Akihiro ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Sunami, Kazutaka ; Katayama, Yoshio ; Yamane, Hiromichi ; Hiraki, Akio ; Harada, Mine. / High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. In: Anticancer Research. 1999 ; Vol. 19, No. 1 B. pp. 693-698.
@article{27fa9c93356e4e98b16af8b8ff3ac389,
title = "High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer",
abstract = "Background: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer) SCLC). Patients and Methods: Eleven patients aged 44 to 63 years old (5 with extensive disease [ED] and 6 with limited disease [LD]) were entered into this study. Induction chemotherapy consisted of 3 to 4 cycles of cisplatin and irinotecan for ED-SCLC, and cisplatin and etoposide for LD-SCLC. Patients with LD-SCLC received concurrent chest radiotherapy along with the first cycle of induction chemotherapy. After induction therapy, peripheral blood progenitor cells (PBPC) were collected following G-CSF administration during a recovery phase from high-dose etoposide (1500 mg/m2). Eight patients (4 with ED and 4 with LD) with adequate organ function were treated with HD-ICE (15 g/m2 ifosfamide, 1200 mg/m2 carboplatin and 1500 mg/m2 etoposide) followed by ABPCT. Results: Hematologic recovery was rapid and non-hematological toxicities were acceptable without treatment related mortality. In ED-SCLC, all of the 4 patients achieved complete response (CR) or near CR but developed a relapse of the isease. In LD-SCLC, 2 of 4 patients with LD-SCLC are alive in continuous CR for 18 and 21 months after the beginning of induction therapy. Conclusions: Despite a limited number of patients and short follow-up time, these preliminary results indicate that marrow-ablative therapy (HD-ICE) supported by ABPCT is feasible in the treatment of elderly patients with LD- and ED-SCLC.",
keywords = "Autologous peripheral blood progenitor cell transplantation, Carboplatin, Etoposide, High-dose chemotherapy, Ifosfamide, Small-cell lung cancer",
author = "Akihiro Bessho and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Kazutaka Sunami and Yoshio Katayama and Hiromichi Yamane and Akio Hiraki and Mine Harada",
year = "1999",
language = "English",
volume = "19",
pages = "693--698",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer

AU - Bessho, Akihiro

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Sunami, Kazutaka

AU - Katayama, Yoshio

AU - Yamane, Hiromichi

AU - Hiraki, Akio

AU - Harada, Mine

PY - 1999

Y1 - 1999

N2 - Background: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer) SCLC). Patients and Methods: Eleven patients aged 44 to 63 years old (5 with extensive disease [ED] and 6 with limited disease [LD]) were entered into this study. Induction chemotherapy consisted of 3 to 4 cycles of cisplatin and irinotecan for ED-SCLC, and cisplatin and etoposide for LD-SCLC. Patients with LD-SCLC received concurrent chest radiotherapy along with the first cycle of induction chemotherapy. After induction therapy, peripheral blood progenitor cells (PBPC) were collected following G-CSF administration during a recovery phase from high-dose etoposide (1500 mg/m2). Eight patients (4 with ED and 4 with LD) with adequate organ function were treated with HD-ICE (15 g/m2 ifosfamide, 1200 mg/m2 carboplatin and 1500 mg/m2 etoposide) followed by ABPCT. Results: Hematologic recovery was rapid and non-hematological toxicities were acceptable without treatment related mortality. In ED-SCLC, all of the 4 patients achieved complete response (CR) or near CR but developed a relapse of the isease. In LD-SCLC, 2 of 4 patients with LD-SCLC are alive in continuous CR for 18 and 21 months after the beginning of induction therapy. Conclusions: Despite a limited number of patients and short follow-up time, these preliminary results indicate that marrow-ablative therapy (HD-ICE) supported by ABPCT is feasible in the treatment of elderly patients with LD- and ED-SCLC.

AB - Background: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer) SCLC). Patients and Methods: Eleven patients aged 44 to 63 years old (5 with extensive disease [ED] and 6 with limited disease [LD]) were entered into this study. Induction chemotherapy consisted of 3 to 4 cycles of cisplatin and irinotecan for ED-SCLC, and cisplatin and etoposide for LD-SCLC. Patients with LD-SCLC received concurrent chest radiotherapy along with the first cycle of induction chemotherapy. After induction therapy, peripheral blood progenitor cells (PBPC) were collected following G-CSF administration during a recovery phase from high-dose etoposide (1500 mg/m2). Eight patients (4 with ED and 4 with LD) with adequate organ function were treated with HD-ICE (15 g/m2 ifosfamide, 1200 mg/m2 carboplatin and 1500 mg/m2 etoposide) followed by ABPCT. Results: Hematologic recovery was rapid and non-hematological toxicities were acceptable without treatment related mortality. In ED-SCLC, all of the 4 patients achieved complete response (CR) or near CR but developed a relapse of the isease. In LD-SCLC, 2 of 4 patients with LD-SCLC are alive in continuous CR for 18 and 21 months after the beginning of induction therapy. Conclusions: Despite a limited number of patients and short follow-up time, these preliminary results indicate that marrow-ablative therapy (HD-ICE) supported by ABPCT is feasible in the treatment of elderly patients with LD- and ED-SCLC.

KW - Autologous peripheral blood progenitor cell transplantation

KW - Carboplatin

KW - Etoposide

KW - High-dose chemotherapy

KW - Ifosfamide

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0032946574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032946574&partnerID=8YFLogxK

M3 - Article

C2 - 10216478

AN - SCOPUS:0032946574

VL - 19

SP - 693

EP - 698

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -